We are live on ! Find out more

Insmed

INSM

Market cap $24.4B

111.59 USD

+14.61

15.06%

At close Updated Oct 29, 4:00 PM EDT

Pre-market

After hours

111.00

-0.59

0.53%

1 day

15.06%

5 days

18.56%

1 month

-3.49%

3 months

8.21%

6 months

-17.36%

Year to date

-37%

1 year

-33.16%

5 years

270.12%

10 years

759.71%

About: Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.

Employees: 1,664

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 31%

Neutral 52.4%

Negative 16.7%

What Insmed (INSM) Said on Its Q3 Earnings Call

Insmed NASDAQ: INSM reported third-quarter 2026 revenue growth from both of its commercial respiratory products and raised the low end of its full-year revenue guidance for BRINSUPRI and ARIKAYCE.

What Insmed (INSM) Said on Its Q3 Earnings Call

Zacks Investment Research

Insmed (INSM) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

While the top- and bottom-line numbers for Insmed (INSM) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Insmed (INSM) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

Zacks Investment Research

Insmed (INSM) Reports Q3 Loss, Tops Revenue Estimates

Insmed (INSM) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to a loss of $1.75 per share a year ago.

Insmed (INSM) Reports Q3 Loss, Tops Revenue Estimates

Insmed Reports Third-Quarter 2026 Financial Results and Provides Business Update

—Total Company Revenues of $524.4 Million for the Third Quarter of 2026— —BRINSUPRI ® (brensocatib) Revenues of $400.1 Million for the Third Quarter of 2026, Reflecting 29% Growth Over the Second Quarter of 2026— —ARIKAYCE ® (amikacin liposome inhalation suspension) Revenues of $124.4 Million for the Third Quarter of 2026, Reflecting 9% Growth Over the Third Quarter of 2025— —Company Raises 2026 BRINSUPRI Revenue Guidance to $1.35 Billion to $1.4 Billion— —Company Raises 2026 ARIKAYCE Revenue Guidance to $460 Million to $470 Million— — Insmed Launches BRINSUPRI Tablets 25 mg (brensocatib hydrate) for the Treatment of Non-Cystic Fibrosis Bronchiectasis in Japan— BRIDGEWATER, N.J., Oct. 29, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today reported financial results for the third quarter ended September 30, 2026, and provided a business update.

Insmed Reports Third-Quarter 2026 Financial Results and Provides Business Update

Zacks Investment Research

Insmed (INSM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Insmed (INSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Insmed (INSM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Insmed Appoints Two New Directors to Its Board

—Paul Hudson, Former CEO of Sanofi and Novartis Pharmaceuticals, and Utpal Koppikar, CFO of Verily Health and Veteran Biopharma Finance Leader, Join as New Independent Directors— BRIDGEWATER, N.J., Oct. 20, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the appointment of Paul Hudson and Utpal Koppikar as independent members of its Board of Directors, effective immediately.

Insmed Appoints Two New Directors to Its Board

Insmed Launches BRINSUPRI® Tablets 25 mg (brensocatib hydrate) for the Treatment of Non-Cystic Fibrosis Bronchiectasis in Japan

—BRINSUPRI, a First-in-Disease and First-in-Class Treatment for Patients With Non-Cystic Fibrosis Bronchiectasis (NCFB), Is Now Available by Prescription in Japan— BRIDGEWATER, N.J., Oct. 19, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the commercial launch in Japan of BRINSUPRI ® Tablets 25 mg (brensocatib hydrate), an oral, once-daily treatment for non-cystic fibrosis bronchiectasis (NCFB) in adults and pediatric patients 12 years and older.

Insmed Launches BRINSUPRI® Tablets 25 mg (brensocatib hydrate) for the Treatment of Non-Cystic Fibrosis Bronchiectasis in Japan

Insmed Features the Global Phase 3 PALM Clinical Development Program Evaluating Treprostinil Palmitil Inhalation Powder (TPIP) at CHEST 2026

—Insmed's Largest Parallel-Running Clinical Effort to Date With Four Pivotal Phase 3 Studies Advancing Across Four Progressive Pulmonary Diseases: PALM-PAH, PALM-ILD, PALM-PPF, and PALM-IPF— —One of the Broadest Active Global Clinical Programs in the Pulmonary Space, With the Potential to Redefine Prostanoid Therapy for These Patient Populations— BRIDGEWATER, N.J., Oct. 15, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, will feature the global PALM Clinical Development Program at the American College of Chest Physicians® Annual Meeting 2026 (CHEST 2026), which is investigating treprostinil palmitil inhalation powder (TPIP) in a range of serious pulmonary diseases.

Insmed Features the Global Phase 3 PALM Clinical Development Program Evaluating Treprostinil Palmitil Inhalation Powder (TPIP) at CHEST 2026

Insmed to Present New Data Across Its Respiratory Portfolio at CHEST 2026 and IDWeek 2026

—Three Late-Breaking Abstracts at CHEST 2026 Deepen Understanding of the Potential of Treprostinil Palmitil Inhalation Powder (TPIP) Across Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)— —New Analysis From the Phase 3 ASPEN Study at CHEST 2026 Provides Additional Insights on Bronchiectasis Management— —Phase 3b ENCORE Study Findings at IDWeek 2026 Examine Amikacin and Macrolide Resistance Development in Patients With Newly Diagnosed Mycobacterium avium Complex (MAC) Lung Disease— BRIDGEWATER, N.J., Oct. 14, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced new data from its respiratory portfolio will be presented at the American College of Chest Physicians® Annual Meeting 2026 (CHEST 2026), taking place Oct. 18–21 in Phoenix, and IDWeek 2026, taking place Oct. 21–24 in Washington, D.C.

Insmed to Present New Data Across Its Respiratory Portfolio at CHEST 2026 and IDWeek 2026

This Insmed Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

This Insmed Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday

See News Rankings

Price charts implemented using Lightweight Charts™